Navigation Links
Conformetrix Appoints Dr Sam Williams as Chief Executive Officer
Date:3/7/2012

MANCHESTER, England, March 7, 2012 /PRNewswire/ --

The Board of Conformetrix Ltd, a leader in optimising drug discovery and design, has appointed Dr Sam Williams as Chief Executive Officer, it is announced today. Dr Williams, who has extensive transactional and business development expertise, was previously a Non-Executive Director of the company. He takes over from one of Conformetrix's founder scientists, Dr Andrew Almond, who becomes Chief Technology Officer.

Conformetrix uses its NMR-based technology to determine the accurate bioactive structures of molecules, an approach which has significant potential in the optimisation of drug discovery and design, as well as the generation of novel drugs. By solving dynamic 3D structures independently of techniques such as X-ray crystallography, the Conformetrix approach derives valuable data more quickly and cheaply than standard approaches. It has been validated by studies both in-house and with partners, and further data and partnering deals are expected this year.

Prior to moving into company management, Dr Williams spent over a decade in the City as a top-rated[1] healthcare analyst, with Robertson Stephens and Lehman Brothers. As well as advising on life sciences investments, he was involved in several IPOs and M&A transactions. Sam has a biology degree from the University of Oxford and a PhD from the University of Cambridge. He will combine his duties at Conformetrix with his role as CEO of Modern Biosciences, a virtual drug development company.

Dr Clive Dix, Chairman of Conformetrix, said, "We welcome Sam as CEO of Conformetrix, where his expertise will be invaluable as the company enters this important next phase of its development. The Board's thanks are also due to Andrew and to Chief Scientific Officer and fellow founder Dr Charles Blundell for their significant contribution to the company's growth so far."

Dr Sam Williams, CEO of Conformetrix, added, "Conformetrix's technology has huge potential in the optimisation of how the pharmaceutical and biotechnology industry generates new pharmaceutical products, and I'm really pleased to be taking on this more active role within the company. The team has expanded significantly during the last year, and I look forward to working with it as Conformetrix matures and moves towards collaborative deals."

[1] Number one-ranked European Biotechnology Analyst in Institutional Investor survey 2004-2006, and in Thomson Extel survey in 2004 and 2005.

Photo available on request

About Conformetrix Ltd

Conformetrix is a Manchester, UK-based company focused on optimising drug discovery and design. It was founded in 2008 as a spin-out from the University of Manchester. The company uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. Since Conformetrix's NMR technology shows what shapes molecules adopt when they are active, it provides high-quality templates for drug discovery and design, and valuable information for drug candidate optimisation. In addition, the data is generated faster and more cheaply than by standard techniques such as X-ray crystallography. Conformetrix has solved biostructures for several large pharmaceutical companies, as well as developing proprietary drug programmes, and has been funded since inception by specialist life science investor Aquarius Equity Partners. For more information, please go to http://www.conformetrix.com.  

For further information please contact:

Conformetrix Ltd
Sam Williams, CEO, +44(0)7881-588-947
Emma Palmer Foster, Strategic Communications Consultant, +44(0)7880-787185
communications@conformetrix.com


'/>"/>
SOURCE Conformetrix Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Idenix Pharmaceuticals Elects Thomas Hodgson as Chairman of the Board and Appoints Michael Wyzga to Its Board of Directors
2. Codexis Appoints Interim Chief Executive Officer
3. Questcor Pharmaceuticals Appoints Scott M. Whitcup, M.D., to Board of Directors
4. UBM Live Appoints Jim Buckley as Informex Brand Director
5. Samsung Medison America Appoints Michael Podany as Vice President of Sales, West USA
6. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
7. Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe
8. Biosyntrx, Inc. Appoints New Board Member & New VP of Operations
9. Octapharma USA Appoints Global Biopharmaceutical Executive David E. Holliday as Vice President of Commercial Development
10. Essentialis Appoints Mahendra G. Shah, Ph.D., to Board of Directors
11. PrimeraDx Appoints David Jackson as VP of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... The latest research Dry eye Drugs Price Analysis and Strategies - ... market. The research answers the following questions: ... clinical attributes? How are they positioned in the Global Dry eye market? ...
(Date:2/24/2017)... Juan Monteverde , founder and managing ... boutique securities firm headquartered at the Empire State Building ... that a class action lawsuit has been filed in the ... Inotek Pharmaceuticals Corporation (NASDAQ:  ITEK)("Inotek" or the "Company") on ... 2015 and December 30, 2016, inclusive (the "Class Period").  ...
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une ... d,annoncer les excellents résultats semestriels clos le 31 décembre ... présentation complète « Résultats et mise à jour sur la ... Faits marquants ... $ ; en hausse de 104 %) Bénéfice ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 2017 , ... With millions of Americans and people worldwide ... all are aware of our options and are empowered with strength and information ... of its newest edition of "Vision and Hearing" in USA Today, that will ...
(Date:2/24/2017)... ... February 24, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... concerning this present generation. Yisrayl makes an astounding statement when he says that ... explains that the Bible details the current times so plainly that anyone should be ...
(Date:2/24/2017)... ... 2017 , ... Congratulations to Head Over Heels’ elite gymnast ... Ms. Esparza qualified into this prestigious status after winning the Vault, Floor, ... Nevada. Frida is one of approximately 25 gymnasts in the nation who earns ...
(Date:2/23/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Beach to host its Swirl: Miami Wine Tasting Event on March 28, 2017. ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a ... content marketing, social media management, corporate communications, SEO and cause marketing, is opening ... in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its ...
Breaking Medicine News(10 mins):